Planta Med 2013; 79(03/04): 301-307
DOI: 10.1055/s-0032-1328174
Natural Product Chemistry
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Heracleifolinosides A–F, New Triterpene Glycosides from Cimicifuga heracleifolia, and Their Inhibitory Activities against Hypoxia and Reoxygenation

Yan-Ru Liu*
1   Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai, Peopleʼs Republic of China
3   Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, Peopleʼs Republic of China
,
Zhi-Jun Wu*
1   Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai, Peopleʼs Republic of China
,
Chun-Tong Li
1   Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai, Peopleʼs Republic of China
,
Feng-Min Xi
1   Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai, Peopleʼs Republic of China
,
Lian-Na Sun
2   School of Pharmacy, Second Military Medical University, Shanghai, Peopleʼs Republic of China
,
Wan-Sheng Chen
1   Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai, Peopleʼs Republic of China
› Author Affiliations
Further Information

Publication History

received 08 August 2012
revised 12 December 2012

accepted 02 January 2013

Publication Date:
30 January 2013 (online)

Preview

Abstract

Six new 9,19-cycloartane triterpene glycosides, heracleifolinosides A–F (16), and one new chromone, norkhelloside (7), were isolated from the rhizome of Cimicifuga heracleifolia, together with 15 known compounds (822). The structures of the new compounds were elucidated by means of spectroscopic methods including 2D NMR and mass spectrometry. The extracts of C. heracleifolia and all the isolated compounds were tested for activities against hypoxia and reoxygenation injury in human umbilical vein endothelial cells. Heracleifolinoside B (2) is effectively resistant to hypoxia and reoxygenation-induced human umbilical vein endothelial cell injury, with cell viabilities of 61.95 ± 2.04 %, 77.04 ± 4.44 %, and 83.65 ± 3.29 % at concentrations of 1, 10, and 100 µM, respectively.

* These two authors contributed equally to the work reported in this article.


Supporting Information